Subject: To understand the usage and performance of Combined oral contraceptives in real-life clinical practice.

Oral contraceptives (OCs), also known as “the pill”, are the most popular method of contraception. However, over the last decades oral contraceptives have undergone extensive study, continual development and significant improvements. Recent development of oral contraceptives has focused on decreasing unwanted side effects. Over the last few decades, reduction of the dose of ethinylestradiol in combined oral contraceptives has decreased the incidence of adverse effects, especially cardiovascular complications. More recently, progestogens with weak or no androgenic effects, or even with antiandrogenic properties, have been developed in the hope of avoiding metabolic disruption. These newer agents may be more suitable for all women due to a better benefit-risk profile.

Dienogest is a novel 19-nortestosterone-derived progestin with a unique pharmacokinetic and pharmacological profile, including antiandrogenic properties. Clinical studies have demonstrated that ethinylestradiol/dienogest is a reliable ovulation inhibitor with high contraceptive efficacy that is comparable with other combined oral contraceptives.

We have planned to conduct a survey to assess the in-practice usage and performance of combined oral contraceptives in real-life clinical practice. We invite you to participate in this surveillance and share your experience.

If you agree to participate, we request you to provide us a copy of relevant information in the standard data collection forms (which we call DCF). You will be responsible for verifying the DCF to ensure that the DCF signed by you are free from errors or omissions.

We trust you and we are partners in ensuring safe and effective drug therapy. In that spirit we hope you will consent to participate in this surveillance. If you do, please sign and return the enclosed reply document along with your visiting card for accuracy of records.

Yours truly,

Mr. Manoj Purandare

SBU Head (Sales & Marketing)
Sun Pharma Laboratories Ltd.
Sun House CTS No. 201 B/1,
Western Express Highway,
Goregaon (E),
Mumbai - 400 063
Tel: + 91 22 4324 1234/4324